Developer docs
API playgroundTry for free, no card

Search company profiles

BenchSci

Full company profile

uuid0000341

Namestring
BenchSci
Legal namestring
Scinapsis Analytics Inc.
Websiteurl
benchsci.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug discovery, biomedical research AI, pharmaceutical research platform, scientific knowledge graphs, reagent selection software
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery AI Platform
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Enterprise Software Licenses
TypeSubscription Recurring
Description

Subscription-based licensing model for pharmaceutical, biotech, and research organizations. Industry Users access the platform through corporate email and paid subscription plans. Academic Users receive free access through institutional email verification at approved post-secondary institutions.

benchsci.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Academic Free Tier
ModelFreemiumBilling cadenceOthers
Notes

Free access for verified academic users affiliated with BenchSci-approved post-secondary institutions, NGOs, and non-profit organizations. Access limited to Antibody tool only unless paid plan purchased.

benchsci.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1ASCEND
Description

A neurosymbolic AI platform that integrates public and proprietary research data into a Biological Evidence Knowledge Graph, enabling researchers to understand disease biology, generate hypotheses, and optimize experimental design.

+2 more records
Core offering1 text field

BenchSci develops and sells AI-powered software platforms (EMET and ASCEND) that accelerate preclinical drug discovery for pharmaceutical and biotechnology companies. Its flagship EMET agentic workbench unifies data, models, workflows, and scientific reasoning into a single environment, while ASCEND is a neurosymbolic AI platform backed by a proprietary Biological Evidence Knowledge Graph with 858M nodes and 2.2B relationships. The platforms help scientists with hypothesis generation, target identification, experiment design, reagent selection, and lead optimization by orchestrating reasoning across 38M+ scientific publications and closed-access papers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60% increase in productivity for Novo Nordisk
+3 more records
Product overview1 text field

BenchSci offers a unified AI-powered platform for preclinical R&D centered on two main products: EMET and ASCEND. EMET is the flagship agentic workbench that provides an orchestration layer for complex scientific reasoning, while ASCEND is the underlying neurosymbolic AI platform featuring a Biological Evidence Knowledge Graph built on Neo4j technology. Within ASCEND, the Selector application helps scientists select reagents and model systems. The platform integrates access to 38M+ scientific publications (including 16M closed-access papers via publisher partnerships), 780K patents, 310K preprints, and proprietary curated data including 16M antibodies, 22M RNAi entries, 18M CRISPR records, 500K cell lines, and 700K animal models. BenchSci serves pharmaceutical companies, biotech firms, and academic institutions (4,500+), with nine of the top ten global pharmaceutical companies as customers.

Product and service4 records
1EMET
CategoryAgentic AI Workbench
Description

EMET is BenchSci's flagship agentic workbench that unifies data, models, software packages, workflows, lab-in-the-loop capabilities, and scientific reasoning into a single environment purpose-built for preclinical R&D. Scientists ask complex research questions in plain language, and the orchestration layer decomposes them, identifies domain-specific skills, and chains them across 38M+ scientific publications (including 16M closed-access papers) to deliver traceable, explainable insights for hypothesis generation, target identification, experiment design, and lead optimization.

2ASCEND
CategoryNeurosymbolic AI Platform
Description

ASCEND is a neurosymbolic AI platform that integrates public and proprietary research data into a Biological Evidence Knowledge Graph, combining foundation models with peer-reviewed literature, multi-omics datasets, and clinical trial evidence. Adopted by nine of the top ten global pharmaceutical companies and 4,500+ research institutions, it helps biopharma scientists evaluate evidence and inform early development decisions.

3Selector
CategoryReagent Selection Application
Description

Selector is an application within the ASCEND platform that uses AI to analyze 27M+ publications and 85M+ products from 450 vendors, recommending suitable reagents (antibodies, CRISPR, proteins, RNAi, cell products, PCR primers) and model systems (animal models) based on experiment context, validation conditions, and bioinformatics data to reduce reagent waste and improve reproducibility.

4LEAP (Life Sciences Evidence-based AI Platform)
CategoryLife Sciences AI Platform
Description

LEAP is a BenchSci life sciences evidence-based AI platform offering launched in November 2025 as part of the company's evolving product portfolio for biomedical research.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Strategic partnership announced June 2026 to create AI-powered tools that combine BenchSci's AI technology with Thermo Fisher's global lab equipment footprint. The collaboration aims to transform preclinical research by enhancing experimental design and scientific data interpretation. This builds on a September 2025 partnership announcement.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-22
Description

Strategic relationship as part of Thermo Fisher's AI ecosystem announcements. BenchSci is among the AI companies partnered with NVIDIA for AI-enabled workflows in pharma and biotech.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-22
Description

Strategic relationship for AI-enabled workflows. BenchSci is included in Thermo Fisher's strategic relationships with AI providers including OpenAI for strengthening data intelligence offerings.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Ongoing partnership with Google for generative AI integration. BenchSci uses Google Gemini for Workspaces internally achieving 89% adoption among employees. The company is also working with Google to validate the MedLM model for life sciences applications.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-03
Description

BenchSci enhances drug discovery by creating a computable map of disease biology using its ASCEND platform built on Neo4j graph database technology. The platform integrates vast biological evidence to facilitate complex research questions, with the knowledge graph linking over 400 million entities and one billion relationships.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

Renewed two-year agreement to support preclinical disease biology research using the ASCEND AI platform. The agreement enhances Merck's efforts to integrate AI into scientific workflows and enables rapid, explainable insights into disease biology. The platform leverages a curated knowledge graph and advanced models to aid early discovery and decision-making.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Multi-year partnership with Mila, Montréal's leading AI research center, to develop AI systems for biological inference and experimental assay prediction. The collaboration aims to advance autonomous drug discovery and enhance predictive generative modeling in biopharmaceutical research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Three-year global license agreement providing Sanofi's worldwide preclinical research organization access to the ASCEND AI platform. The neurosymbolic AI system integrates public and proprietary research data into a Biological Evidence Knowledge Graph, enabling researchers to better understand disease biology, generate hypotheses, and optimize experimental design across Sanofi's global research sites.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Atomwise applies AI (AtomNet) to small-molecule drug discovery and partners with major pharma on preclinical pipelines — closely comparable to BenchSci's AI-for-preclinical-discovery positioning, with similar enterprise licensing motion into pharma.

TypeBroad incumbent
Description

Recursion is a publicly traded AI-driven drug discovery company combining high-throughput experimental biology with foundation models — broadly comparable to BenchSci as a larger, more vertically integrated incumbent in AI drug discovery spanning both platform and pipeline assets.

TypeEmerging player
Description

Cradle applies generative AI to protein engineering and biologics design — an emerging player with partial overlap to BenchSci's AI-for-biology positioning, focused specifically on biologics rather than the broader preclinical scope.

TypeDirect peer
Description

Owkin applies AI to biomedical research with a strong focus on multi-omics and clinical data, partnering with pharma — comparable to BenchSci's multi-omics-enabled Biological Evidence Knowledge Graph and pharma-enterprise GTM.

TypeBroad incumbent
Description

Schrödinger is a publicly traded computational chemistry and molecular simulation platform serving pharma — a broad incumbent comparable to BenchSci in computational tools for preclinical research but more focused on physics-based simulation than knowledge-graph reasoning.

TypeDirect peer
Description

Insitro is a machine-learning-driven drug discovery company combining high-throughput biology with AI models to predict drug behavior — directly comparable to BenchSci in applying AI/ML to preclinical pharma R&D, with overlapping customer base among large pharma.

7Iambic Therapeutics
TypeEmerging player
Description

Iambic is an early-stage AI drug discovery company combining neural network potentials with experimental chemistry — an emerging peer with partial overlap to BenchSci's preclinical AI focus, narrower in therapeutic scope but technically adjacent.

8Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs (Alphabet/DeepMind spin-out) builds AI for drug discovery with major pharma partnerships — directly comparable to BenchSci's ASCEND/EMET as an AI-driven preclinical platform competing for the same pharma enterprise accounts and discovery workflows.

TypeEmerging player
Description

EvolutionaryScale develops frontier AI models for biology (ESM family of protein language models) — thematically adjacent to BenchSci's orchestration of biological foundation models (ESM-2, AbLang2), positioning them as both potential partner and competitor in AI-for-biology infrastructure.

TypeDirect peer
Description

Exscientia is an AI-driven drug discovery company with both platform and pipeline assets and major pharma partnerships — a direct peer to BenchSci in applying AI to preclinical pharma discovery with overlapping customer base among top-10 pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BenchSci

Drug Discovery AI Platformbenchsci.com

BenchSci firmographics

Firmographics
Name
BenchSci
Legal name
Scinapsis Analytics Inc.
Website
https://benchsci.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

BenchSci industry classification

Industry
Product category
Drug Discovery AI Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Preclinical drug discovery
  • Biomedical research AI
  • Pharmaceutical research platform
  • Scientific knowledge graphs
  • Reagent selection software

Where BenchSci is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

BenchSci business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Enterprise Software Licenses: Subscription-based licensing model for pharmaceutical, biotech, and research organizations. Industry Users access the platform through corporate email and paid subscription plans. Academic Users receive free access through institutional email verification at approved post-secondary institutions.

Pricing tiers

ModelBillingPrice
FreemiumOthersAcademic Free Tier

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

BenchSci product offering

Product offering

Core offering

BenchSci develops and sells AI-powered software platforms (EMET and ASCEND) that accelerate preclinical drug discovery for pharmaceutical and biotechnology companies. Its flagship EMET agentic workbench unifies data, models, workflows, and scientific reasoning into a single environment, while ASCEND is a neurosymbolic AI platform backed by a proprietary Biological Evidence Knowledge Graph with 858M nodes and 2.2B relationships. The platforms help scientists with hypothesis generation, target identification, experiment design, reagent selection, and lead optimization by orchestrating reasoning across 38M+ scientific publications and closed-access papers.

Product overview

BenchSci offers a unified AI-powered platform for preclinical R&D centered on two main products: EMET and ASCEND. EMET is the flagship agentic workbench that provides an orchestration layer for complex scientific reasoning, while ASCEND is the underlying neurosymbolic AI platform featuring a Biological Evidence Knowledge Graph built on Neo4j technology. Within ASCEND, the Selector application helps scientists select reagents and model systems. The platform integrates access to 38M+ scientific publications (including 16M closed-access papers via publisher partnerships), 780K patents, 310K preprints, and proprietary curated data including 16M antibodies, 22M RNAi entries, 18M CRISPR records, 500K cell lines, and 700K animal models. BenchSci serves pharmaceutical companies, biotech firms, and academic institutions (4,500+), with nine of the top ten global pharmaceutical companies as customers.

Differentiator

Problem solved

Functional benefit

Brands

  • ASCEND: A neurosymbolic AI platform that integrates public and proprietary research data into a Biological Evidence Knowledge Graph, enabling researchers to understand disease biology, generate hypotheses, and optimize experimental design.
  • EMET
  • Selector

Products and services

  • EMET EMET is BenchSci's flagship agentic workbench that unifies data, models, software packages, workflows, lab-in-the-loop capabilities, and scientific reasoning into a single environment purpose-built for preclinical R&D. Scientists ask complex research questions in plain language, and the orchestration layer decomposes them, identifies domain-specific skills, and chains them across 38M+ scientific publications (including 16M closed-access papers) to deliver traceable, explainable insights for hypothesis generation, target identification, experiment design, and lead optimization.
  • ASCEND ASCEND is a neurosymbolic AI platform that integrates public and proprietary research data into a Biological Evidence Knowledge Graph, combining foundation models with peer-reviewed literature, multi-omics datasets, and clinical trial evidence. Adopted by nine of the top ten global pharmaceutical companies and 4,500+ research institutions, it helps biopharma scientists evaluate evidence and inform early development decisions.
  • Selector Selector is an application within the ASCEND platform that uses AI to analyze 27M+ publications and 85M+ products from 450 vendors, recommending suitable reagents (antibodies, CRISPR, proteins, RNAi, cell products, PCR primers) and model systems (animal models) based on experiment context, validation conditions, and bioinformatics data to reduce reagent waste and improve reproducibility.
  • LEAP (Life Sciences Evidence-based AI Platform) LEAP is a BenchSci life sciences evidence-based AI platform offering launched in November 2025 as part of the company's evolving product portfolio for biomedical research.

Quantifiable outcome

  • 60% increase in productivity for Novo Nordisk
  • +3 more outcomes

Companies that use BenchSci

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

BenchSci technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

BenchSci partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship, strategic and core.

  • Thermo Fisher ScientificflagshipStrategic or Co-development Partner · 22 June 2026Strategic partnership announced June 2026 to create AI-powered tools that combine BenchSci's AI technology with Thermo Fisher's global lab equipment footprint. The collaboration aims to transform preclinical research by enhancing experimental design and scientific data interpretation. This builds on a September 2025 partnership announcement.
  • NVIDIAstrategicTechnology or Integration · 22 June 2026Strategic relationship as part of Thermo Fisher's AI ecosystem announcements. BenchSci is among the AI companies partnered with NVIDIA for AI-enabled workflows in pharma and biotech.
  • OpenAIstrategicTechnology or Integration · 22 June 2026Strategic relationship for AI-enabled workflows. BenchSci is included in Thermo Fisher's strategic relationships with AI providers including OpenAI for strengthening data intelligence offerings.
  • GooglestrategicTechnology or Integration · 17 March 2026Ongoing partnership with Google for generative AI integration. BenchSci uses Google Gemini for Workspaces internally achieving 89% adoption among employees. The company is also working with Google to validate the MedLM model for life sciences applications.
  • Neo4jcoreTechnology or Integration · 3 March 2026BenchSci enhances drug discovery by creating a computable map of disease biology using its ASCEND platform built on Neo4j graph database technology. The platform integrates vast biological evidence to facilitate complex research questions, with the knowledge graph linking over 400 million entities and one billion relationships.
  • MerckcoreStrategic or Co-development Partner · 9 December 2025Renewed two-year agreement to support preclinical disease biology research using the ASCEND AI platform. The agreement enhances Merck's efforts to integrate AI into scientific workflows and enables rapid, explainable insights into disease biology. The platform leverages a curated knowledge graph and advanced models to aid early discovery and decision-making.
  • MilastrategicStrategic or Co-development Partner · 13 November 2025Multi-year partnership with Mila, Montréal's leading AI research center, to develop AI systems for biological inference and experimental assay prediction. The collaboration aims to advance autonomous drug discovery and enhance predictive generative modeling in biopharmaceutical research.
  • SanoficoreStrategic or Co-development Partner · 10 October 2025Three-year global license agreement providing Sanofi's worldwide preclinical research organization access to the ASCEND AI platform. The neurosymbolic AI system integrates public and proprietary research data into a Biological Evidence Knowledge Graph, enabling researchers to better understand disease biology, generate hypotheses, and optimize experimental design across Sanofi's global research sites.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

BenchSci competitors and assessment

Company assessment

Direct peers

  • Atomwise: Atomwise applies AI (AtomNet) to small-molecule drug discovery and partners with major pharma on preclinical pipelines — closely comparable to BenchSci's AI-for-preclinical-discovery positioning, with similar enterprise licensing motion into pharma.
  • Owkin: Owkin applies AI to biomedical research with a strong focus on multi-omics and clinical data, partnering with pharma — comparable to BenchSci's multi-omics-enabled Biological Evidence Knowledge Graph and pharma-enterprise GTM.
  • Insitro: Insitro is a machine-learning-driven drug discovery company combining high-throughput biology with AI models to predict drug behavior — directly comparable to BenchSci in applying AI/ML to preclinical pharma R&D, with overlapping customer base among large pharma.
  • Isomorphic Labs: Isomorphic Labs (Alphabet/DeepMind spin-out) builds AI for drug discovery with major pharma partnerships — directly comparable to BenchSci's ASCEND/EMET as an AI-driven preclinical platform competing for the same pharma enterprise accounts and discovery workflows.
  • Exscientia: Exscientia is an AI-driven drug discovery company with both platform and pipeline assets and major pharma partnerships — a direct peer to BenchSci in applying AI to preclinical pharma discovery with overlapping customer base among top-10 pharma.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion is a publicly traded AI-driven drug discovery company combining high-throughput experimental biology with foundation models — broadly comparable to BenchSci as a larger, more vertically integrated incumbent in AI drug discovery spanning both platform and pipeline assets.
  • Schrödinger: Schrödinger is a publicly traded computational chemistry and molecular simulation platform serving pharma — a broad incumbent comparable to BenchSci in computational tools for preclinical research but more focused on physics-based simulation than knowledge-graph reasoning.

Emerging players

  • Cradle Bio: Cradle applies generative AI to protein engineering and biologics design — an emerging player with partial overlap to BenchSci's AI-for-biology positioning, focused specifically on biologics rather than the broader preclinical scope.
  • Iambic Therapeutics: Iambic is an early-stage AI drug discovery company combining neural network potentials with experimental chemistry — an emerging peer with partial overlap to BenchSci's preclinical AI focus, narrower in therapeutic scope but technically adjacent.
  • EvolutionaryScale: EvolutionaryScale develops frontier AI models for biology (ESM family of protein language models) — thematically adjacent to BenchSci's orchestration of biological foundation models (ESM-2, AbLang2), positioning them as both potential partner and competitor in AI-for-biology infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BenchSci social profiles

Digital presence

BenchSci compliance and trust

Trust signal

Compliance1 record

BenchSci financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BenchSci leadership team

Management profile

Number of profiles

Profiles9 records

BenchSci funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BenchSci M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BenchSci

What does BenchSci do?

BenchSci develops and sells AI-powered software platforms (EMET and ASCEND) that accelerate preclinical drug discovery for pharmaceutical and biotechnology companies. Its flagship EMET agentic workbench unifies data, models, workflows, and scientific reasoning into a single environment, while ASCEND is a neurosymbolic AI platform backed by a proprietary Biological Evidence Knowledge Graph with 858M nodes and 2.2B relationships. The platforms help scientists with hypothesis generation, target identification, experiment design, reagent selection, and lead optimization by orchestrating reasoning across 38M+ scientific publications and closed-access papers.

Is BenchSci a public or private company?

BenchSci is a private company. It is classified as venture growth investor backed and is currently operating.

When was BenchSci founded?

BenchSci was founded in 2016. It employs 101 to 250 people.

Where is BenchSci based?

BenchSci is headquartered in Toronto, Canada, in the North America region.

How does BenchSci make money?

One revenue line is on record: enterprise Software Licenses.

Who are BenchSci's main competitors?

Direct peers on record are Atomwise, Owkin, Insitro, Isomorphic Labs and Exscientia. Broad incumbents are Recursion Pharmaceuticals and Schrödinger. Emerging players are Cradle Bio, Iambic Therapeutics and EvolutionaryScale.

Does BenchSci have an API?

No public API is recorded for BenchSci.

What industry is BenchSci in?

BenchSci's product category is Drug Discovery AI Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug DiscoveryBenchSci announced a two-year enterprise agreement with argenx to deploy its EMET AI platform for preclinical drug discovery. The platform unifies data, models, and workflows, reasoning across 38M+ publications and databases. The deal marks BenchSci's expansion in European biopharma.Financial PostBenchSci Partners with Google Cloud to Close Biology's Infrastructure GapBenchSci announced a multi-year initiative making Google Cloud the primary infrastructure platform for EMET, its agentic research environment for preclinical drug discovery. The combined solution gives scientists access to BenchSci's knowledge graph of 858 million nodes, 2.2 billion edges, and 16 million closed-access papers, plus AlphaGenome and AlphaFold 3. BenchSci, which raised over $200 million, is integrating EMET into the Google Cloud Marketplace.FinancialContent Business PageBenchSci Partners with Google Cloud to Close Biology's Infrastructure GapBenchSci announced a multi-year initiative placing EMET, its agentic research environment for preclinical drug discovery, on Google Cloud as its primary infrastructure platform. The solution combines BenchSci's knowledge graph of 858 million nodes, 2.2 billion edges and 16 million closed-access papers with Google's AlphaGenome and AlphaFold 3. BenchSci says 80% of users report 60% efficiency gains, and is integrating EMET into the Google Cloud Marketplace.YahooBenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the BoardBenchSci appointed Dr. Mikael Dolsten, former Pfizer R&D Chief, as its first Chairman of the Board effective June 2026 to oversee governance and long-term strategy for its AI platform EMET. The appointment follows the successful launch of EMET, which reports efficiency gains of up to 60% among users in major pharmaceutical companies. This leadership change aims to support BenchSci's expansion across global biopharma and academic research institutions.Built InVP of Marketing (AI-Native & Autonomous Operations) - BenchSciBenchSci is hiring a VP of Marketing to lead its brand and demand generation efforts in biopharma R&D, focusing on establishing itself as a leader in AI-powered drug discovery. The role involves building an autonomous, AI-driven marketing infrastructure from scratch, with significant strategic and operational responsibilities. The candidate will operate in a highly autonomous, innovative environment, leveraging AI tools and infrastructure.openPR.comGlobal Drivers Overview: The Rapid Evolution of the Preclinical CRO MarketThe preclinical CRO market is forecast to reach $9.83 billion by 2030, growing at a 9.5% CAGR, driven by demand for precision medicine, rare disease drugs, biologics, and strategic partnerships between pharmaceutical companies and CROs. In September 2024, PharmaLegacy Laboratories, a US-based preclinical drug development CRO, completed the acquisition of BTS Research to expand its in vitro and in vivo service offerings and boost study capacity across North America. BenchSci, a Canada-based AI solutions provider, launched its ASCEND platform in February 2023 to enhance preclinical drug discovery through machine learning analysis.BenchSci BlogWe’re All in on Generative AI—Here’s How It’s Changing The Way We WorkBenchSci, a life sciences technology company, has adopted an 'AI-first' company philosophy and integrated generative AI tools including Google Gemini for Workspaces and NotebookLM across its operations, achieving 89% adoption of Gemini among employees.BenchSci BlogHacking for the Future: How BenchSci Unleashes Innovation with GenAI TechBenchSci, an AI company serving pharmaceutical research, conducted its third company-wide hackathon focused on Generative AI technology, bringing together 45 participants from Engineering, Product, and Science teams across Canada, the US, and the UK. The virtual event produced multiple projects that have already been brought into production, including a prompt debugger tool and solutions for querying and visualizing scientific pathways. The company highlighted its ongoing partnership with Google to validate the MedLM model and noted that its ASCEND platform has enabled customers like Novo Nordisk to achieve a 60% increase in productivity.Graph Database & AnalyticsBenchSci Decodes Disease Biology with Neo4j to Accelerate Drug DiscoveryBenchSci has built a neuro-symbolic AI platform called ASCEND using Neo4j graph database technology to create a computable map of disease biology, enabling pharmaceutical companies to accelerate and de-risk preclinical research; the platform is now deployed by 9 of the top 10 global pharmaceutical companies and over 4,500 research institutions. The Biological Evidence Knowledge Graph integrates evidence from tens of millions of scientific publications and proprietary datasets to address the structural failure in drug discovery, where over 90% of clinical trials fail due to misunderstood biology, at an average cost of $2.5 billion per drug. BenchSci has partnered with Thermo Fisher Scientific to create a "Lab-in-the-Loop" system integrating computational reasoning with physical laboratory execution, and is collaborating with Mila (Quebec AI Institute) on graph machine learning to predict novel biological relationships.Analytics InsightBenchSciBenchSci is a Toronto-based AI healthcare company focused on transforming drug discovery and preclinical research globally. It provides AI-powered solutions and platforms that support pharmaceutical, biotech, and research organizations to accelerate scientific discovery and improve outcomes.